A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Background:
Pembrolizumab (P) is an anti-PD-1 antibody that blocks the interaction between programmed cell death protein 1 (PD-1) on T-cells and PD-L1 and PD-L2 on tumour cells. A phase Ib trial of P plus chemotherapy was undertaken to evaluate the safety and efficacy.
Methods:
Patients with advanced, metastatic solid tumours were enrolled...
Alternative Titles
Full title
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5520208
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5520208
Other Identifiers
ISSN
0007-0920
E-ISSN
1532-1827
DOI
10.1038/bjc.2017.145
